Page 155 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)

3- Lomitapide

 Microsomal Triglyceride Transfer Protein (MTP) inhibitors
Mechanism
 Bind and inhibit MTP from transferring TG to apo B in liver

 decrease in VLDL & LDL-C
Effect  Useful in homozygous FH who lack LDL-R
 Reduces LDL-C (42-50%)

Dose Initially orally 5mg/day, 10, 20, 40 up to 60 mg

 Approved for ttt of homozygous FH with restriction hepatotoxicity
Use  available through restricted Risk Evaluation & Mitigation Strategy
(REMS) program

| P a g e - 139 -